NI201300007A - Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol. - Google Patents

Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.

Info

Publication number
NI201300007A
NI201300007A NI201300007A NI201300007A NI201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A
Authority
NI
Nicaragua
Prior art keywords
csf
stimulating factor
conjugate
granulocite
cologne
Prior art date
Application number
NI201300007A
Other languages
English (en)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Leonidovna Morozova Elena
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300007A publication Critical patent/NI201300007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicinas, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G -CSF) con la fórmula general: (I) Donde: n - intergers de 681 a 1,000; m - interger 4; NªH - G - CSF - Natural o recombinante polipéptido, teniendo actividad de G - CSF. La invención También está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir y/o tratar la neutropenia, el contenedor que contiene la composición farmacéutica.
NI201300007A 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol. NI201300007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе

Publications (1)

Publication Number Publication Date
NI201300007A true NI201300007A (es) 2014-05-26

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300007A NI201300007A (es) 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.

Country Status (18)

Country Link
KR (1) KR101549457B1 (es)
CN (1) CN103140499B (es)
CL (1) CL2013000400A1 (es)
CO (1) CO6670557A2 (es)
CR (1) CR20130020A (es)
CU (1) CU24139B1 (es)
DO (1) DOP2013000003A (es)
EA (1) EA019043B1 (es)
EC (1) ECSP13012399A (es)
MA (1) MA34525B1 (es)
MY (1) MY160732A (es)
NI (1) NI201300007A (es)
PE (1) PE20131085A1 (es)
PH (1) PH12012502426A1 (es)
RS (1) RS20130094A1 (es)
RU (1) RU2446173C1 (es)
SG (1) SG187572A1 (es)
WO (1) WO2012021088A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
US10519209B2 (en) * 2014-07-14 2019-12-31 Gennova Biopharmaceuticals Limited Process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
IL295406B1 (en) * 2020-03-17 2026-06-01 Drugrecure Aps Liquid formulation of GM-CSF for inhalation
EP4121448A2 (en) * 2020-03-20 2023-01-25 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases

Also Published As

Publication number Publication date
MY160732A (en) 2017-03-15
CU20130012A7 (es) 2013-04-19
RS20130094A1 (sr) 2013-08-30
WO2012021088A1 (en) 2012-02-16
DOP2013000003A (es) 2013-07-31
SG187572A1 (en) 2013-03-28
KR101549457B1 (ko) 2015-09-02
EA201101035A1 (ru) 2012-02-28
RU2446173C1 (ru) 2012-03-27
CU24139B1 (es) 2015-12-23
CN103140499A (zh) 2013-06-05
KR20130043167A (ko) 2013-04-29
CO6670557A2 (es) 2013-05-15
PE20131085A1 (es) 2013-10-10
MA34525B1 (fr) 2013-09-02
CL2013000400A1 (es) 2013-07-26
CR20130020A (es) 2013-02-20
CN103140499B (zh) 2014-12-17
ECSP13012399A (es) 2013-05-31
PH12012502426A1 (en) 2021-06-02
EA019043B1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
CO6670557A2 (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
PH12014500249A1 (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
BR112013031268A8 (pt) polipeptídeos
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
MX354102B (es) Derivados de bencimidazol-prolina.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
UA103221C2 (uk) Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
MX2014013095A (es) Forma de dosificacion farmaceutica termoconformada, resistente al uso indebido, que contiene zinc.
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
BR112012024712A2 (pt) antagonistas do receptor vaniloide trpv1 com uma porção bicíclica
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
PH12014502619A1 (en) Novel dosage and formulation
MX373378B (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
TR201007250A2 (tr) Selobioz içeren formülasyon.
AR074470A1 (es) Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
PL399880A1 (pl) 8-(oktadecylosulfanylo)chinolina do zastosowania jako lek, zwlaszcza do stosowania w leczeniu i profilaktyce rozwoju insulinoopornosci, kompozycja farmaceutyczna zawierajaca 8-(oktadecylosulfanylo)chinoline oraz zastosowanie 8-(oktadecylosulfanylo)chinoliny do wytwarzania leku do stosowania w leczeniu i profilaktyce rozwoju insulinoopornosci
UA99014C2 (ru) Метиловый эстер n-[(2-оксоиндолинилиден-3)-2-оксиацетил]аминоуксусной кислоты, который проявляет противовоспалительное действие